Loading...
Burzynski Research Institute, Inc.
BZYR•PNK
HealthcareBiotechnology
$0.04
$0.00(0.00%)
Burzynski Research Institute, Inc. (BZYR) Stock Overview
Explore Burzynski Research Institute, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.01
↓ 45.74%
EPS Growth
$-0.01
↓ 45.71%
Operating Margin
0.00%
↓ 45.74%
ROE
2223.80%
↓ 45.74%
Dividend Yield
0.00%
Analyst Recommendations data is not available for BZYRAnalyst Recommendations details for BZYR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
CEO
Dr. Stanislaw R. Burzynski M.D., Ph.D.
Headquarters
9432 Katy Freeway, Houston, TX
Founded
1997